Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for cancer and rare diseases, appointed Kristin Yarema, company president, cell therapy. “Kristin brings extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy to Poseida, and I am excited to welcome her to our leadership team,” said Mark Gergen, CEO. “With her strategic, business and scientific background, she is a proven leader who ...